PARP1 and cancer: Preclinical studies suggest that cancer cells with alterations in other homologous recombination (HR) repair pathway genes (e.g., ataxia telangiectasia mutated (ATM) and partner and localizer of BRCA2 (PALB2) may also be sensitive to PARP inhibition9–12.